First Data On Cytonet GmbH & Co. KG’s Liver Cell Therapy For Urea Cycle Disorders Presented At The Annual Meeting Of The Society For Inherited Metabolic Disorders (SIMD)

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Interim data on the use of liver cell therapy (LCT) for the treatment of pediatric patients with Urea Cycle Disorders (UCD) were presented today at the Annual Meeting of the Society for Inherited Metabolic Disorders (SIMD) in Pacific Grove, California.

UCD is a rare, potentially life-threatening liver metabolism disorder that in its severe form can affect newborns and infants, causing toxic levels of ammonia to accumulate in the body, which can lead to massive and irreversible damage of the nervous system including the brain.

Help employers find you! Check out all the jobs and post your resume.

Back to news